Search Results - "Maykut, R"

The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthma by Braunstahl, G.-J, Chen, C.-W, Maykut, R, Georgiou, P, Peachey, G, Bruce, J

“…Summary Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of outcomes in real-world clinical practice is needed to…”
Get full text

Persistency of response to omalizumab therapy in severe allergic (IgE‐mediated) asthma by Bousquet, J., Siergiejko, Z., Świebocka, E., Humbert, M., Rabe, K. F., Smith, N., Leo, J., Peckitt, C., Maykut, R., Peachey, G.

“…To cite this article: Bousquet J, Siergiejko Z, Świebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G. Persistency of response to…”
Get full text

Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data by Molimard, M, Buhl, R, Niven, R, Le Gros, V, Thielen, A, Thirlwell, J, Maykut, R, Peachey, G

“…Summary Background Long-term oral corticosteroid (OCS) therapy is associated with significant burden on patients and healthcare resources; treatments that may…”
Get full text

WS01.2 TOBI® for eradication of early P. aeruginosa infection in paediatric cystic fibrosis patients: the EARLY study by Ratien, F, Alon, N, Maykut, R, Liu, C, Angyalosi, G

Get full text

Reductions In Oral Corticosteroid Use In Patients With Allergic (IgE- Mediated) Asthma Receiving Omalizumab by Braunstahl, G, Maykut, R, Figliomeni, M, Chen, C, Peachey, G

Get full text

72 Inspiratory flow characteristics of the T-326 dry powder inhaler (DPI) in CF patients by Geller, D, Ament, B, Heuerding, S, Maykut, R, Pavkov, R

Get full text

Adding Omalizumab to the Therapy of Adolescents With Persistent Uncontrolled Moderate—Severe Allergic Asthma by Massanari, M., Milgrom, H., Pollard, S., Maykut, R.J., Kianifard, Farid, Fowler-Taylor, A., Geba, G.P., Zeldin, R.K.

“…Objective. This study aimed to evaluate the effectiveness of omalizumab among adolescents with moderate—severe allergic asthma inadequately controlled with…”
Get full text

Effect of Omalizumab on Asthma Control and Quality of Life in Patients with Moderate-Severe Persistent IgE-Mediated Asthma and Allergy to House Dust Mite by Maykut, R, Massanari, M, Kianifard, F, Zeldin, R

“…The number of asthma exacerbations was analyzed using Poisson regression Change from baseline in overall Juniper Adult Asthma Quality of Life Questionnaire…”
Get full text

Addition of Omalizumab Improved Functional Health Status in Patients With Impaired Quality of Life Associated With Moderate-Severe Persistent Allergic Asthma by Massanari, M, Sacco, P, Kianifard, F, Maykut, R, Zeldin, R

“…Rationale A significant number of patients with moderate-severe asthma are not well controlled and consequently have impaired quality of life (QoL) despite…”
Get full text

Clinically Relevant Improvements in Asthma-Related Quality of Life in Patients Receiving Omalizumab as Add-On Therapy by Busse, W., Fox, H., Surrey, K., Maykut, R., Reisner, C.

“…Significantly more patients achieved clinically meaningful improvements in AQLQ score from baseline in the omalizumab group (66.3%) than in the control group…”
Get full text

In Moderate-Severe Asthma, Omalizumab Reduced the Need for Rescue Systemic Steroid Bursts and Improved Ratings of Treatment Effectiveness: A Pooled Analysis by Maykut, R., Massanari, M., Zeldin, R., Kianifard, F., Deniz, Y., Reisner, C., Geba, G.

“…In moderate-severe asthmatics, omalizumab significantly reduced the need for rescue bursts of steroids which was highly associated with investigator and…”
Get full text

Treatment of Chronic Autoimmune Urticaria with Omalizumab by Kaplan, A.P, Joseph, K, Maykut, R.J, Zeldin, R.K

“…Rationale Approximately 40% of patients with chronic urticaria have an IgG antibody directed to the α-subunit of the high affinity IgE receptor (chronic…”
Get full text

Implementation of guidelines for preoperative laboratory investigations in patients scheduled to undergo elective surgery by Larocque, B J, Maykut, R J

“…To assess the impact on preoperative laboratory investigations in elective surgery after the implementation of guidelines for ordering such tests. A…”
Get full text

Pathophysiology and implications for treatment of acute respiratory distress syndrome by van Soeren, M H, Diehl-Jones, W L, Maykut, R J, Haddara, W M

“…Acute respiratory distress syndrome is a complex group of signs and symptoms caused by direct or indirect lung injury. In spite of decades of research, it is…”
Get more information

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma: Persistency of response to omalizumab by Bousquet, J., Siergiejko, Z., Świebocka, E., Humbert, M., Rabe, K. F., Smith, N., Leo, J., Peckitt, C., Maykut, R., Peachey, G.

Get full text

PR3 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) by Dean, BB, Calimlim, B, Aguilar, D, Sacco, P, Maykut, R, Tinkelman, D

Get full text

PRS31 IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON CHILD AND CAREGIVER PRODUCTIVITY by Dean, BB, Calimlim, B, Aguilar, D, Sacco, P, Maykut, R, Tinkelman, D

Get full text

Omalizumab Reduced Need for Steroid Bursts and Improved Treatment Effectiveness in Asthmatics on Inhaled Salmeterol and Fluticasone Combination Therapy by Massanari, M., Kianifard, F., Maykut, R., Zeldin, R., Hedgecock, S., Reisner, C., Geba, G.

Get full text

Omalizumab Reduced Need for Steroid Bursts in Asthmatics Concomitantly Using Leukotrine Receptor Antagonists (LTRAs) by Zeldin, R., Massanari, M., Maykut, R., Kianifard, F., Deniz, Y., Reisner, C., Geba, G.

Get full text

Effect of Omalizumab on Pulmonary Function and Asthma-related Outcome Measures in Patients Allergic to Cat Dander by Massanari, Marc, Associate Medical Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Maykut, Robert, Medical Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Zeldin, Robert, Executive Medical Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Kianifard, Farid, Statistician, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Geba, Gregory, Therapeutic Area Head, Novartis Pharmaceuticals Corporation, Verona, NJ

Get full text